Monitor whether the in-hospital channel can stabilize as management cited a one-off issue at two hospitals; the pharma R&D pipeline recovery is key given the 38.6% segment decline. Cash runway of ~4 quarters at current burn rate suggests potential need for capital raise if trends persist.
Price Chart
Executive Summary
Burning Rock Biotech reported Q1 2026 revenue of RMB107.9M ($15.6M), down 18.9% YoY, with net loss widening to RMB17.5M from RMB13.5M. All three revenue channels declined, led by a 38.6% drop in pharma R&D services, while gross margin contracted slightly to 72.3%. The company continues to burn cash with operating cash outflow of RMB29.3M in the quarter.
Key Financial Metrics
Key Facts
- Q1 2026 revenue RMB107.9M ($15.6M), down 18.9% YoY from RMB133.1M
- Net loss widened to RMB17.5M ($2.5M) vs RMB13.5M in Q1 2025
- Pharma R&D services revenue fell 38.6% YoY to RMB22.8M
- Central lab revenue down 15.3% YoY; in-hospital revenue down 8.5% YoY
- Gross margin slipped to 72.3% from 73.2% a year ago
- Operating cash outflow of RMB29.3M ($4.2M) vs RMB23.5M in prior year period
- Cash and restricted cash at RMB448.7M ($65.1M) as of March 31, 2026
Financial Impact
Revenue decline of 18.9% YoY with widening losses and cash burn acceleration
Risk Factors
- Continued revenue contraction across all three channels
- Cash burn accelerating with no path to profitability visible
- Dependence on pharma R&D services which are lumpy and declining
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $11.62 $15.20 | ▼ −30.81% | ▼ −28.68% | $11.75 (−1.12%) |
Sep 10, 2026 6w ago | 6-K | $11.62 $15.20 | ▼ −30.81% | ▼ −28.68% | $11.75 (−1.12%) |
Jun 9, 2026 19w ago | Press Release | $8.18 $10.75 | ▼ −31.36% | ▼ −29.91% | $11.75 (−43.64%) |
Jun 9, 2026 19w ago | 6-K | $8.18 $10.75 | ▼ −31.36% | ▼ −29.91% | $11.75 (−43.64%) |
Apr 28, 2026 25w ago | Press Release | $16.65 $12.17 | ▼ −26.91% | ▼ −32.36% | $11.75 (−29.43%) |
Mar 12, 2026 32w ago | Press Release | $22.85 $15.85 | ▼ −30.66% | ▼ −32.63% | $11.75 (−48.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers